Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $34 from $31 and keeps an Overweight rating on the shares after the company reported 12-week data from the Ph2 MoonStone trial of obexelimab in relapsing MS. 24-week data due in Q1 of 2026 will inform further development, the analyst noted.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Promising Phase 2 Results and Strategic Licensing Drive Buy Rating for Zenas BioPharma
- Zenas BioPharma price target raised to $46 from $27 at Citi
- Zenas BioPharma price target raised to $44 from $30 at H.C. Wainwright
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- Zenas BioPharma Reports Positive Phase 2 Trial Results